ArticleCirculation2022
Coronary Artery and Cardiac Disease in Patients With Type 2 Myocardial Infarction: A Prospective Cohort Study.
Article in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03338504 (Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- 2022 ACC Expert Consensus Decision Pathway on the Evaluation and Disposition of Acute Chest Pain in the Emergency Department: A Report of the American College of Cardiology Solution Set Oversight Committee.Journal of the American College of Cardiology · 2022Guideline
- Absence of chest discomfort in type 1 NSTEMI patients: predictors and impact on outcome.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Contemporary Challenges and Strategies for Diagnosing and Managing in Type 2 Myocardial Infarction: A Narrative Review.Journal of personalized medicine · 2026Review
- Phenotype-Specific Gradients of NT-proBNP Reflect Distinct Functional and Structural Remodeling Signatures in Heart Failure.Journal of clinical medicine · 2026Article
- Maximum Troponin As an Independent Predictor of 30- and 90-day Mortality in Type 2 Myocardial Infarction.Critical pathways in cardiology · 2026Article
- Prevalence and Prognostic Implications of Atherosclerotic Coronary Artery Disease in Type 2 Myocardial Infarction.JACC. Advances · 2026Article
- Anginal Symptoms in Patients With Type 2 Myocardial Infarction: Insights From the TARGET-Type 2 Trial.JACC. Advances · 2026Article
- Type 2 Myocardial Infarction: Navigating Diagnostic Pathways and Therapeutic Crossroads Between Invasive and Conservative Strategies.Journal of clinical medicine · 2026Review
- Balancing Bleeding and Ischemic Risk: Dual Antiplatelet Therapy in a 90-Year-Old Man With Myocardial Infarction and Gastrointestinal Bleeding.The American journal of case reports · 2026Article
- Article
- An easy-to-use model for screening type 2 myocardial infarction in geriatric patients with acute coronary syndrome: a retrospective cohort study.Frontiers in medicine · 2026Article
- Myocardial injury in patients with acute ischemic stroke: Prevalence and types of triggers of myocardial demand ischemia.European stroke journal · 2026Article
- Cardiovascular and non-cardiovascular mortality at 5 years in patients with type 1 and type 2 myocardial infarction.European heart journal. Acute cardiovascular care · 2025Article
- The assessment and management of patients with type 2 myocardial infarction: an international Delphi study.European heart journal. Quality of care & clinical outcomes · 2025Article
- Incidence and In-Hospital Outcomes of Bradycardia or Atrioventricular Conduction Disorder in Patients With Type 2 Myocardial Infarction: A Nationwide Inpatient Analysis.Journal of arrhythmia · 2025Article
- Identification of Clinical Phenotypes in Type 2 Myocardial Infarction: Insights Into Characteristics, Prognosis, and Management Strategies.Journal of the American Heart Association · 2025Article
- Implications of a new clinical classification of acute myocardial infarction.European heart journal. Acute cardiovascular care · 2025Article
- Implications of a new clinical classification of acute myocardial infarction.European heart journal. Acute cardiovascular care · 2025Observational
- Type 2 myocardial infarction: challenges in diagnosis and treatment.European heart journal · 2025Review
- Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
23 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundType 2 myocardial infarction is caused by myocardial oxygen supply-demand imbalance, and its diagnosis is increasingly common with the advent of high-sensitivity cardiac troponin assays. Although this diagnosis is associated with poor outcomes, widespread uncertainty and confusion remain among clinicians as to how to investigate and manage this heterogeneous group of patients with type 2 myocardial infarction.
methodsIn a prospective cohort study, 8064 consecutive patients with increased cardiac troponin concentrations were screened to identify patients with type 2 myocardial infarction. We excluded patients with frailty or renal or hepatic failure. All study participants underwent coronary (invasive or computed tomography angiography) and cardiac (magnetic resonance or echocardiography) imaging, and the underlying causes of infarction were independently adjudicated. The primary outcome was the prevalence of coronary artery disease.
resultsIn 100 patients with a provisional diagnosis of type 2 myocardial infarction (median age, 65 years [interquartile range, 55-74 years]; 43% women), coronary and cardiac imaging reclassified the diagnosis in 7 patients: type 1 or 4b myocardial infarction in 5 and acute myocardial injury in 2 patients. In those with type 2 myocardial infarction, median cardiac troponin I concentrations were 195 ng/L (interquartile range, 62-760 ng/L) at presentation and 1165 ng/L (interquartile range, 277-3782 ng/L) on repeat testing. The prevalence of coronary artery disease was 68% (63 of 93), which was obstructive in 30% (28 of 93). Infarct-pattern late gadolinium enhancement or regional wall motion abnormalities were observed in 42% (39 of 93), and left ventricular systolic dysfunction was seen in 34% (32 of 93). Only 10 patients had both normal coronary and normal cardiac imaging. Coronary artery disease and left ventricular systolic dysfunction were previously unrecognized in 60% (38 of 63) and 84% (27 of 32), respectively, with only 33% (21 of 63) and 19% (6 of 32) on evidence-based treatments.
conclusionsSystematic coronary and cardiac imaging of patients with type 2 myocardial infarction identified coronary artery disease in two-thirds and left ventricular systolic dysfunction in one-third of patients. Unrecognized and untreated coronary or cardiac disease is seen in most patients with type 2 myocardial infarction, presenting opportunities for initiation of evidence-based treatments with major potential to improve clinical outcomes. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03338504.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.